FDA: Factoring In Reimbursement, U.S. Bests Europe In Access To Innovative Devices

FDA officials refute claims, frequently made by industry, that because FDA’s PMA review process is much slower than the CE mark regulatory process in Europe, Americans suffer delayed access to innovative and life-saving technology.